Form 8-K - Current report:
SEC Accession No. 0001193125-25-116023
Filing Date
2025-05-08
Accepted
2025-05-08 16:34:43
Documents
15
Period of Report
2025-05-08
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d916048d8k.htm   iXBRL 8-K 24709
2 EX-99.1 d916048dex991.htm EX-99.1 36694
6 GRAPHIC g916048g0508010244564.jpg GRAPHIC 4480
  Complete submission text file 0001193125-25-116023.txt   193560

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA aclx-20250508.xsd EX-101.SCH 2838
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE aclx-20250508_lab.xml EX-101.LAB 17235
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE aclx-20250508_pre.xml EX-101.PRE 10804
17 EXTRACTED XBRL INSTANCE DOCUMENT d916048d8k_htm.xml XML 3494
Mailing Address 800 BRIDGE PARKWAY REDWOOD CITY CA 94065
Business Address 800 BRIDGE PARKWAY REDWOOD CITY CA 94065 240-327-0603
Arcellx, Inc. (Filer) CIK: 0001786205 (see all company filings)

EIN.: 472855917 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41259 | Film No.: 25926870
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)